文献速递头颈部肿瘤放疗

多西他赛、顺铂、5-氟尿嘧啶诱导化疗后西妥昔单抗放射免疫治疗联合碳离子加量调强放疗治疗口咽、下咽及喉局部晚期肿瘤的II期研究

Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx.
PubMed 文献 · Clin Transl Radiat Oncol · 2018-09-21

这项前瞻性、单中心、开放标签、非随机II期试验因入组缓慢提前终止,单臂入组8例局部晚期口咽、下咽及喉鳞癌患者,接受多西他赛、顺铂、5-氟尿嘧啶诱导化疗后西妥昔单抗联合碳离子加量(24Gy(RBE)/8次)与IMRT(50 Gy/25次)放疗。中位随访13个月,12个月局部区域肿瘤控制率、无进展生存率和总生存率均为100.0%,7例达完全缓解;治疗可耐受且有前景,多数生活质量方面至末次随访恢复。

要点

  • 8例局部晚期口咽、下咽及喉鳞癌患者入组,试验因入组缓慢提前终止。
  • 12个月局部区域控制率、无进展生存率、总生存率均为100.0%,7例完全缓解。
  • 12个月最常见晚期放疗不良事件为口干(85.7%),4例发生5起严重不良事件且均恢复。

核心结论

  • 研究治疗可耐受且有前景。
  • 多数方面的生活质量下降在末次随访前恢复。

研究设计与样本

  • 前瞻性、单中心、开放标签、非随机II期试验,因入组缓慢提前终止。
  • 单治疗臂:多西他赛、顺铂、5-氟尿嘧啶诱导化疗后西妥昔单抗联合碳离子加量(24Gy(RBE),8次)与IMRT(50 Gy,25次)。
  • 共入组8例患者,中位年龄52.5岁。

主要发现

  • 中位随访13个月,12个月局部区域肿瘤控制率、无进展生存率和总生存率均为100.0%。
  • 7例患者达到完全缓解。
  • 12个月最常见晚期放疗不良事件为口干,发生率85.7%。
  • 4例患者记录5起严重不良事件且均恢复:黏膜炎3级(n=2)、淋巴细胞计数下降4级、发热性中性粒细胞减少4级、西妥昔单抗过敏反应3级(各n=1)。
  • 多数症状量表最差值出现在末次治疗日,至第4次随访恢复。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验因入组缓慢提前终止。
  • 仅入组8例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This phase II trial was designed to evaluate efficacy and safety of a highly intensified therapy in locally advanced squamous cell carcinoma of the oro-, hypopharynx and larynx. METHODS: In this prospective, mono-centric, open-label, non-randomized phase II trial the single treatment arm consisted of a combined induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, followed by bioradiation with the monoclonal antibody cetuximab, carbon ion boost (24Gy(RBE) in 8 fractions) and IMRT (50 Gy in 25 fractions). The trial was closed early due to slow accrual. RESULTS: Eight patients (median age 52.5 years) were enrolled into the trial. The median follow-up was 13 months and the 12-months locoregional tumor control, progression-free survival and overall survival rates were 100.0% each. Complete remission was achieved in 7 patients. The most commonly late radiation adverse event was xerostomia (85.7% at 12 months). Five serious adverse events with recovery were documented in 4 patients: mucositis grade 3 (n = 2), decreased lymphocyte count grade 4, febrile neutropenia grade 4 and hypersensitivity grade 3 to cetuximab (n = 1 each). Most symptom scales had their worst value at the last treatment day and recovered until the 4th follow-up visit. CONCLUSION: The study treatment was tolerable and promising. Reduced quality of life recovered for most aspects until the last follow-up visit.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hauswald H, Jensen AD, Krauss J, et al. Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. Clin Transl Radiat Oncol. 2018. PMID: 30370340. doi:10.1016/j.ctro.2018.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。